Adjuvant therapy with Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) in patients with resected renal cell carcinoma was ...

Active surveillance (“watch and wait”) functioned as a strategy to monitor biology while preserving sequencing flexibility for subsequent therapies. Living long-term with cancer means learning to live ...

Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...

Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...

The third and final day of the 2026 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium highlighted important developments in kidney cancer treatment, including combination ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

Overall, day two of ASCO GU emphasized that advances in therapy must go hand-in-hand with patient-centered research. These ...

CURE ® readers have a unique opportunity each year to honor oncology nurses who have helped guide them through the cancer experience. Many thoughtful nomination essays are prepared and submitted by ...

At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.

Kidney cancer is not exclusively a disease of older patients. For many young adults, the diagnosis comes as a shock, often appearing without warning in those who otherwise feel healthy.

Longitudinal PRO modeling, rather than time-to-worsening censoring, indicated maintained HRQOL and pain outcomes with ...

Mehra added that research in head and neck cancer is entering an exciting phase, with growing interest in bispecific antibodies targeting EGFR. With newer dual-targeting agents, including Rybrevant, ...